Contract facts
NONENo full NAICS 541714 intel page yet. Browse NAICS intelligence
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Auravax Therapeutics, Inc. Estimated value $750K ($750K obligated). Current period of performance ends Dec 31, 2026. Last award drew 1 bidder. Place of performance: HOUSTON TX. Related solicitation 22-100-SOL-00003.
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN
Recompete timing
PublicCurrent PoP ends Dec 31, 2026 (115 days remaining). Agencies typically plan 12–18 months ahead — at 3.8 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordAuravax Therapeutics, Inc — $750K obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50124C00054?
75A50124C00054 (Auravax auravax overall objective THIS contract) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $750K, currently held by Auravax Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50124C00054?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50124C00054 to Auravax Therapeutics, Inc (potential $750K).
Who is the incumbent on 75A50124C00054?
Auravax Therapeutics, Inc is the incumbent with $750K across 1 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2026.
When does Auravax Therapeutics, Inc’s 75A50124C00054 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Seen enough? Run one full capture cycle on 75A50124C00054 — $90 for 90 days.
This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.
$1/day · one payment · no subscription
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.